Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial

  title={Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial},
  author={Hans Peter Volz and Hans-J{\"u}rgen M{\"o}ller and Ingrid W. Reimann and K. D. Stoll},
  journal={European Neuropsychopharmacology},
Psychopharmacotherapy of somatoform disorders: effects of opipramol on symptoms of somatization, anxiety, and depression
The well-tolerated anxiolytic opipramol is the first psychotropic drug with proven efficacy in somatoform disorders with effects on symptoms of somatization, anxiety, and depression.
Opipramol for the Treatment of Generalized Anxiety Disorder: A Placebo-Controlled Trial Including an Alprazolam-Treated Group
It was demonstrated for the first time that opipramol, a strong but nonselective sigma site ligand, possesses anxiolytic efficacy superior to placebo in the treatment of GAD.
Efficacy of Treatment for Somatoform Disorders: A Review of Randomized Controlled Trials
  • K. Kroenke
  • Medicine, Psychology
    Psychosomatic medicine
  • 2007
CBT is the best established treatment for a variety of somatoform disorders, with some benefit also demonstrated for a consultation letter to the primary care physician.
Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial
In this 12-week, randomized, placebo-controlled study, escitalopram (10–20 mg/day) was both effective and well tolerated in the treatment of patients with MSD.
St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial
This is the first study showing the efficacy of a drug in patients with somatisation disorder independent of depressive symptomatology, and excellent efficacy and tolerability for LI 160 in somatoform disorders are shown.
Psychopharmacotherapy of somatic symptoms disorders
Five principal groups of drugs such as tricyclic antidepressants (TCA), serotonin reuptake inhibitors (SSRI), serotonin and noradrenalin reuptakes inhibitors (SNRI), atypical antipsychotics and herbal medication are systematically studied and evidence indicates that all five groups are effective in a wide range of disorders.
Treatment of Somatoform Disorders With St. John's Wort: A Randomized, Double-Blind and Placebo-Controlled Trial
Administration of 600 mg of SJW extract LI 160 daily is effective and safe in the treatment of somatoform disorders, thereby confirming results from a previous study.
[Update Opipramol].
In view of the limited availability of (pharmacologic) treatment options for generalized anxiety disorder and particularly somatoform disorders, opipramol should be considered in the treatment of these entities.
Pharmacological interventions for somatoform disorders in adults.
A systematic review and meta-analysis of placebo-controlled studies examined the efficacy and tolerability of different types of antidepressants, the combination of an antidepressant and an antipsychotic, antipsychotics alone, or natural products in adults with somatoform disorders in adults to improve optimal treatment decisions.
Efficacy of functional relaxation and patient education in the treatment of somatoform heart disorders: a randomized, controlled clinical investigation.
Functional relaxation appears to be a safe and effective, non-pharmacological approach in the treatment of non-specific chest pain.


Opipramol in the climacteric syndrome. A double-blind, placebo-controlled trial.
A Comparative Trial of Opipramol and Chlordiazepoxide in the Treatment of Anxiety
Although opipramol appeared to give more relief of somatic anxiety, the difference was not statistically significant and the total number of side effects recorded was similar on both drugs although drowsiness occurred twice as frequently on chlordiazepoxide as it did on opipramsol.
Somatoform disorders--diagnostic concept, controlled clinical trials, and methodological issues.
The present study discusses methodological requirements for clinical trials, including inclusion and exclusion criteria, measurements of efficacy and safety, and statistical considerations, in the hope that this will stimulate the use of this diagnostic entity in the future.
The Bradford Somatic Inventory. A multi-ethnic inventory of somatic symptoms reported by anxious and depressed patients in Britain and the Indo-Pakistan subcontinent.
In the development and evaluation of a multi-ethnic inventory (the BSI) of somatic symptoms associated with anxiety and depression, symptoms were derived from psychiatric case notes of Pakistani and
A Comparative Trial of Insidon and Stelazine in the Treatment of Anxiety
In a double-blind comparison of opipramol and trifluoperazine the symptom ‘anxiety’ was found to be statistically more improved in the opipramsol group of patients.
Observations on clinical aspects of hysteria; a quantitative study of 50 hysteria patients and 156 control subjects.
The study was undertaken to determine whether the clinical impression of the relatively constant pattern of hysteria was a true impression, to provide factual data that might be useful to the clinician in the diagnosis of hysteria, and to provide a sound clinical basis for further research in hysteria.
Comparative Evaluation of Rating Scales for Clinical Psychopharmacology
The method of evaluation and comparison of rating scales and the results of the comparative evaluation of scales for the assessment of psychotic behaviour and recommendations are described.
Somatization in the community: relationship to disability and use of services.
It is found that respondents meeting criteria for somatization reported a heavier use of health services than non-somatizers; of those respondents Meeting criteria for a psychiatric diagnosis, somatizers preferentially used medical over mental health services whereas non-Somatizer reported the opposite trend.